Formålet med studien:  This is a Phase 1 trial to investigate the safety and efficacy of the investigational drug, DCC-2618, administered orally (PO), in adult patients with advanced malignancies.
Sponsor:  Deciphera Pharmaceuticals LLC
Kontaktopplysninger for rettssaken:  Divya Sakamuri; 1-713-745-3296; dsakamuri@mdanderson.org or Filip Janku; 713-563-1930; FJanku@mdanderson.org
Ønsket pasientmedvirkning:  ECD patients 18 years or older.
Kjente sentre som tar imot ECD-pasienter i studien:  MD Anderson, Houston, Texas
ClinicalTrials.gov-identifikator:  NCT02571036